Neptune Technologies & Bioressources, Inc. Subsidiary Acasti Pharma, Inc. Warrant Exercise Deadline on November 17, 2010
October 28 2010 - 7:30AM
Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT)
(TSX-V:NTB) ("Neptune"):
Acasti Pharma Inc. ("Acasti")
value creation milestones achieved between August 2008 and October
2010.
Corporate operations & structure:
- Acquisition of worldwide rights for cardiovascular
pharmaceutical applications through an exclusive license from
Neptune Technologies & Bioressources Inc.
- Financing of $2.5M by private placement at $0.20 for 12.5M
shares and warrants (exercise price $0.40; expiration Dec
31-2010)
- Implementation of a management team with solid pharmaceutical
experience
- Creation of a first-class world renowned scientific advisory
board
- Represented by key-opinion-leaders at American Heart
Association 2010 Scientific Sessions
- Establishment of strong professional partnerships
- Early 2010, Acasti's common share evaluated at $0.47 as
presented in Neptune's audited financial statements for fiscal year
ended February 28, 2010
- FY2010/11-Q3 Aggregate potential proceed of $9,5M from warrant
exercises expiring November-December 2010
- Filing of a Listing Application with TSX-Venture authorities to
list Acasti's shares expected before the end of Acasti's current
fiscal year
Research and Product Development:
Three products developed:
-- Prescription drug (CaPre™)
- Strengthening of intellectual property portfolio with new
pharmaceutical patent application
- Completion of CTA-enabling preclinical trials
- Confirmed superiority of CaPre™ over drugs prescribed for the
management of high triglycerides
- Preclinical data showing benefits for patients with
dyslipidemia, diabetes and metabolic syndrome
- FY2010/11-Q3 positive pre-Clinical Trial Application (CTA)
meeting with Health Canada in order to enter a Phase II trial for
cardiovascular conditions in Canada
- Positive pre-IND feedbacks in preparation for a Phase III
filing to the FDA for the USA
- CTA approval pending
-- Medical food (Onemia™)
- Successful manufacturing of Onemia™, a novel
omega-3:phospholipid formulation
- Compliance of Onemia™ with FDA Medical Food regulations
- Implementation of commercial & operational strategies to
generate short-term revenues
- FY2010/11-Q3 Market launch of Onemia™ for the management of
cardiometabolic disorders
-- Over-the-counter (Vectos™)
- Preclinical data showing benefits for patients with
dyslipidemia and metabolic syndrome
- Ongoing out-licensing negotiations with future pharmaceutical
partners for global commercialization
- Strengthening of intellectual property portfolio with new
pharmaceutical patent application
Short Term Objectives / Milestones
- Approval of Clinical Trial Application (CTA) for Phase II with
CaPre™ in Canada
- Listing with TSX-Venture authorities of Acasti shares
- Initiation of Phase II clinical study with CaPreTM in
Canada
- Submission of IND-application for Phase III clinical study in
USA
- Short-term revenues from commercialization of Onemia™ in the
USA
- Completion of OTC-Vectos™ development and manufacturing
- Out-license the commercialization of OTC-Vectos™ to
pharmaceutical partner
All material information contained in this press release was
already fully disclosed publicly by Acasti and/or Neptune. We
invite the reader to consult the public documentation (financial
statements, press releases, information circulars, etc.) previously
filed on SEDAR by Acasti and/or Neptune for more information.
NEPTUNE TECHNOLOGIES & BIORESSOURCES,
INC. SUBSIDIARY ACASTI PHARMA, INC.
WARRANT EXERCISE DEADLINE ON NOVEMBER 17, 2010
Dear Warrant holder,
Acasti Pharma Inc. ("Acasti") Series II
Warrants ("Acasti Warrants"), each exercisable at
$0.40 per share ("Exercise Price") expire at 5PM
on November 17, 2010 ("Expiration
Date").
We recommend you read hereabove Acasti's value creation
milestones achieved between August 2008 and October
2010. Should you want to exercise your warrants
before Expiration Date, please follow the procedure below.
Procedure
To exercise your Acasti Warrants, you need to execute and
complete one of the following procedures before the Expiration
Date:
1. If your Acasti Warrants are held in a brokerage account:
You need to instruct your broker to exercise Acasti Warrants and
he will inform you on the brokerage firm procedure, which should be
completed before the Expiration Date.
2. If your Acasti Warrants are held in a online brokerage
account:
You need to call your brokerage firm information line and they
will instruct you on the process to exercise your Acasti Warrants,
which should be completed before the Expiration Date.
3. If you have the warrant certificate in hand:
You need to send a certified cheque, or money draft, for the
aggregate exercise price payable to Acasti Pharma along with the
duly completed exercise form, on the back of the warrant
certificate, to the attention of Computershare Trust Company, 1500
University, 7th floor, Montreal (Quebec) H3A 3S8.
4. If you had the warrant certificate in hand and lost it:
You need to notify Computershare by sending a lost warrant
certificate form (find the form on the following website:
http://www.neptunebiotech.com/acasti-warrants/lost ).
For further explanation or any question, please consult
http://www.neptunebiotech.com/acasti-warrants or call:
Computershare 1 (800) 564-6253, Acasti at (450) 686-4555 or Neptune
at 1-800-664-9166 or (450) 687-2262; ask for Andre Godin (CFO) or
Xavier Harland (Director of finance).
Thank you for your confidence and support.
Henri Harland, CEO |
Tina Sampalis,
President |
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide. Neptune is the mother company of Acasti and
NeuroBioPharm.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group
Bob Beaty
1 (888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024